SAN FRANCISCO, Oct. 8, 2025 /PRNewswire/ — Bunkerhill Health today announced that it has received U.S. Food and Drug Administration (FDA) clearance for Bunkerhill MAC, the first artificial intelligence algorithm to detect and quantify mitral annular calcification (MAC). The algorithm runs on routine, non-gated chest CT scans.
ntuitive Surgical (Nasdaq: ISRG)+
announced today that it received FDA clearance for new software advancements for its Ion endoluminal robot.
Engineering and health researchers at the University of Waterloo have developed a radar and artificial intelligence (AI) system that can monitor multiple people walking in busy hospitals and long-term care facilities to identify possible health issues.
Vektor Medical today announced it received CE mark approval for its vMap artificial intelligence-powered arrhythmia mapping system.
Researchers at McMaster University and the Massachusetts Institute of Technology (MIT) have made two scientific breakthroughs at once: they not only discovered a brand-new antibiotic that targets inflammatory bowel diseases (IBD), but also successfully used a new type of AI to predict exactly how the drug works. To their knowledge, this is a global first for the AI.
If you’ve been to a medical appointment recently, you may have already interacted with AI. As you describe your symptoms to the doctor, they may ask your permission to use an “AI scribe” to convert audio into medical notes in real time.
MIT CSAIL and McMaster researchers used a generative AI model to reveal how a narrow-spectrum antibiotic attacks disease-causing bacteria, speeding up a process that normally takes years.
McGill University researchers have developed an artificial intelligence tool that can detect previously invisible disease markers inside single cells.
Scientists at the University of Liverpool have developed a new low-cost blood test that could make it easier to detect Alzheimer’s disease at an earlier stage—helping patients receive treatment and support sooner.
NEW YORK, Sept. 30, 2025 /PRNewswire/ — Aidoc, the global leader in clinical AI, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company’s novel multi-triage solution that flags a wide array of life-threatening, time-sensitive medical conditions, all within a single workflow. Built on CARE™, the first clinical-grade foundation model in healthcare with FDA cleared solutions, and deployed through Aidoc’s aiOS™ platform, the solution is designed to help care teams attend to high–risk cases faster and more consistently across the health system.